193 related articles for article (PubMed ID: 31898311)
1. Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors?
Martínez-López S; García-Martínez A; Torregrosa-Quesada ME; López-Muñoz B; Cámara R; Fajardo C; Lamas C; Picó A
J Endocrinol Invest; 2020 Jun; 43(6):859-863. PubMed ID: 31898311
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
3. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression.
Corbetta S; Ballaré E; Mantovani G; Lania A; Losa M; Di Blasio AM; Spada A
Eur J Clin Invest; 2001 Mar; 31(3):208-14. PubMed ID: 11264647
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
[TBL] [Abstract][Full Text] [Related]
7. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
8. DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors.
Kober P; Rymuza J; Baluszek S; Maksymowicz M; Nyc A; Mossakowska BJ; Zieliński G; Kunicki J; Bujko M
Neuroendocrinology; 2024; 114(1):51-63. PubMed ID: 37699356
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.
Ben-Shlomo A; Liu NA; Melmed S
Pituitary; 2017 Feb; 20(1):93-99. PubMed ID: 27900635
[TBL] [Abstract][Full Text] [Related]
10. Lower
Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.
Gil J; Marques-Pamies M; Valassi E; Serra G; Salinas I; Xifra G; Casano-Sancho P; Carrato C; Biagetti B; Sesmilo G; Marcos-Ruiz J; Rodriguez-Lloveras H; Rueda-Pujol A; Aulinas A; Blanco A; Hostalot C; Simó-Servat A; Muñoz F; Rico M; Ibáñez-Domínguez J; Cordero E; Webb SM; Jordà M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1129213. PubMed ID: 37033229
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
13. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
Yoshihara A; Isozaki O; Hizuka N; Nozoe Y; Harada C; Ono M; Kawamata T; Kubo O; Hori T; Takano K
Endocr J; 2007 Feb; 54(1):133-8. PubMed ID: 17159301
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
17. Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.
Gabalec F; Drastikova M; Cesak T; Netuka D; Masopust V; Machac J; Marek J; Cap J; Beranek M
Physiol Res; 2015; 64(3):369-77. PubMed ID: 25536318
[TBL] [Abstract][Full Text] [Related]
18. Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment.
Trouillas J; Vasiljevic A; Lapoirie M; Chinezu L; Jouanneau E; Raverot G
Minerva Endocrinol; 2019 Jun; 44(2):129-136. PubMed ID: 30531694
[TBL] [Abstract][Full Text] [Related]
19. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
[TBL] [Abstract][Full Text] [Related]
20. Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs.
Sato A; Hara Y
Res Vet Sci; 2018 Aug; 119():61-66. PubMed ID: 29864631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
